Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: Results of the 6-month ELIZA trial

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 535-549

  Radchenko, G D ^a   Sirenko, Y M ^a   Kushnir, S M ^a   Torbas, O O ^a   Dobrokhod, A S ^a  

^a Ukranian Strazhesko Institute of Cardiology   (Ukraine)

Author keywords

Arterial hypertension; Arterial stiffness; Central blood pressure; Combination therapy

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; BISOPROLOL FUMARATE; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; DOXAZOSIN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LORISTA HD; TENOX; UNCLASSIFIED DRUG;

ADULT; AGED; ANKLE EDEMA; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BLOOD CHEMISTRY; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BODY MASS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ELECTROCARDIOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART RATE; HEART VENTRICLE EJECTION TIME; HOT FLUSH; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL EDEMA; PULSE PRESSURE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL;

ARTERIAL HYPERTENSION; ARTERIAL STIFFNESS; CENTRAL BLOOD PRESSURE; COMBINATION THERAPY;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BISOPROLOL; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; CHI-SQUARE DISTRIBUTION; DIURETICS; DOXAZOSIN; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PULSE WAVE ANALYSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UKRAINE; VASCULAR STIFFNESS;

EID: 84889795692     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S44568     Document Type: Article

References (85)

1. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
2. Gil-Extremera B. ABPM study: efficacy of two fixed dose combinations, enalapril/nitrendipine versus. losartan/hydrochlorothiazide, in not controlled mild-moderate hypertensive patients. Am J Hypertens. 2003;16:A116.
3. Wilson TW, Lacourcière Y, Barnes CC. The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group. CMAJ. 1998;159:469-476.
4. Dahlof B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
5. Bangalore S, Wild D, Parkar S, Kukin M, Messerli FH. Beta-blockers for primary prevention of heart failure in patients with hypertension: insights from a meta-analysis. J Am Coll Cardiol. 2008;52:1062-1072.
6. Panjrath G, Messerli F. Beta-blockers for primary prevention in hypertension: era bygone? Prog Cardiovasc Dis. 2006;49:76-87.
7. Cruickshank J. Beta-blockers continue to surprise us. Eur Heart J. 2000;21:354-364.
8. Mancia G. Prevention of risk factors: beta-blockade and hypertension. Eur Heart J. 2009;11:A3-A8.
9. Everly MJ, Heaton PC, Cluxton RJ Jr. Beta-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother. 2004;38:286-293.
10. Lopez-Sendon J, Swedberg K, McMurray J, et al; Task Force On Beta-Blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25:1341-1362.
11. Rydén L, Standl E, Bartnik M, et al; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines in diabetes, prediabetes and cardiovascular disease: full text. Eur Heart J. 2007;28:88-136.
12. Roman M, Devereux R, Kizer J, et al. High central pulse pressure is independently associated with adverse cardiovascular outcome the strong heart study. J Am Coll Cardiol. 2009;54:1730-1734.
13. Roman M, Devereux R, Kizer J, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure. The Strong Heart Study. Hypertension. 2007;50:197-203.
14. Williams B, Lacy P. Impact of heart rate on central aortic pressures and hemodynamic analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J Am Coll Cardiol. 2009;54:705-713.
15. Benetos A, Consoli S, Safavian A, Dubanchet A, Safar M. Efficacy, safety and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. Am Heart J. 2000;140:11E.
16. Brion R, Carre F, Verdier J, et al. Comparative effects of bisoprolol and nitrendipine on exercise capacity in hypertensive patients with regular physical activity. J Cardiovasc Pharmacol. 2000;35:78-83.
17. Czuriga I, Riecansky I, Bodnar J, et al; NEBIS Investigators Group. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the nebivolol, bisoprolol multicenter study (NEBIS). Cardiovasc Drugs Ther. 2003;17:257-263.
18. Wang B, Song W, Liu G. The effect long-term administration of a selective beta1 blocker bisoprolol on glucose metabolism in patients with essential hypertensive and type 2 diabetes mellitus. Zhonghua Nei Ke Za Zhi. 2005;44:503-505. Chinese.
19. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trail: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur Heart J. 2001;3:469-479.
20. Ong K, Delerme S, Pannier B, et al. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J Hypertens. 2011;29:1034-1132.
21. Greenwald S. Pulse pressure and arterial elasticity. QJM. 2002;95: 107-112.
22. Karamanoglu M, O'Rourke MF, Avolio AP, Kelly RP. An analysis of the relationship between central aortic and peripheral upper limb pressure waves in man. Eur Heart J. 1993;14:160-167.
23. Safar M. Macro and Microcirculation in Hypertension. London, UK: Lippincott Williams & Wilkins; 2005.
24. Wilkinson I, Franklin S, Hall I, Tyrrell S, Cockroft JR. Pressure amplification explains why pulse pressure is unrelated to risk in young subjects. Hypertension. 2001;38:1461-1466.
25. O'Brien E, Asmar R, Beilin L, et al; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003;21:821-848.
26. Sirenko Y. Arterial Hypertension. Kiev, Ukraine: Morion; 2002.
27. White W. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics. Totowa, NJ: Humana Press; 2001.
28. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38:938-942.
29. Cameron JD, McGrath BP, Dart AM. Use of radial artery applanation tonometry and a generalized transfer function to determine aortic pressure augmentation in subjects with treated hypertension. J Am Coll Cardiol. 1998;32:1214-1220.
30. Cohn J. Is it the blood pressure or the blood vessel? Am J Hypertens. 2007;1:5-16.
31. Ichihara A, Hayashi M, Kaneshiro Y, et al. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis. 2005;45:866-874.
32. Labat C, Lacolley P, Lajemi M, de Gasparo M, Safar ME, Benetos A. Effects of valsartan on mechanical properties of the carotid artery in spontaneously hypertensive rats under high-salt diet. Hypertension. 2001;38:439-443.
33. London GM, Asmar RG, O'Rourke MF, Safar ME. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/ indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol. 2004;43:92-99.
34. Mackenzie I, McEniery C, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension. 2009;54:409-413.
35. Safar ME, Blacher J, Pannier B, et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension. 2002;39:735-738.
36. Kario K. Clinician's Manual on Early Morning Risk Management in Hypertension. London, UK: Science Press; 2004.
37. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol. 2000;525:263-270.
38. Antikainen R, Jousilahti P, Tuomilehto J. Systolic blood pressure, isolated systolic hypertension and risk of coronary heart disease, strokes, cardiovascular disease and all-cause mortality in the middle-aged population. J Hypertens. 1998;16:577-583.
39. London G. Central blood pressure reduction: a key to organ protection. Medicographia. 2005;27:144-147.
40. Nichols W, O'Rourke M. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles, 5th ed. London, UK: Hodder Arnold; 2005.
41. Nakamura M, Sato K, Nagano M. Estimation of aortic systolic blood pressure in community-based screening: the relationship between clinical characteristics and peripheral to central blood pressure differences. J Hum Hypertens. 2005;19:251-253.
42. Sharman JE, Stowasser M, Fassett RG, Marwick TH, Franklin SS. Central blood pressure measurement may improve risk stratification. J Hum Hypertens. 2008;22:838-844.
43. Dart AM, Gatzka CD, Kingwell BA, et al. Brachial blood pressure but not carotid arterial waveforms predict cardiovascular events in elderly female hypertensives. Hypertension. 2006;47:785-790.
44. Gómez-Marcos MA, Recio-Rodríguez JI, Rodríguez-Sánchez E, et al. Central blood pressure and pulse wave velocity: relationship to target organ damage and cardiovascular morbidity-mortality in diabetic patients or metabolic syndrome. An observational prospective study. LOD-DIABETES study protocol. BMC Public Health. 2010;10:143.
45. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236-1241.
46. McEniery C, McDonnell Y, Munnery M, et al; Anglo-Cardiff Collaborative Trial Investigators. Variability and impact of cardiovascular risk factors the Anglo-Cardiff Collaborative Trial II. Hypertension. 2008;51:1476-1482.
47. McEniery C, Yasmin, Hall I, Qasem A, Wilkinson IB, Cockcroft JR; ACCT Investigators. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol. 2005;46:1753-1760.
48. O'Rourke, Seward J. Central arterial pressure and arterial pressure pulse: new views entering the second century after Korotkov. Mayo Clin Proc. 2006;81:1057-1068.
49. Pini R, Cavallini M, Palmieri V, et al. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population. The ICARe Dicomano Study. J Am Coll Cardiol. 2008;51:2432-2439.
50. Williams B, Lacy PS, Thom SM. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation. 2006;113:1213-1225.
51. Tsang TS, Verzosa GC, Barnes ME, et al. Central pulse pressure as a robust predictor of first atrial fibrillation: Study of Atrial Fibrillation In High Risk Elderly (SAFFIHRE). Circulation. 2008;118:1106.
52. Kullo I, Bielak L, Turner S, Sheedy P, Peyser P. Aortic pulse wave velocity is associated with the presence and quantity of coronary artery calcium: a community-based study. Hypertension. 2006;47:174-179.
53. Nelson M, Stepanek J, Cevette M, Covalciuc M, Hurst RT, Tajik AJ. Noninvasive measurement of central vascular pressures with arterial tonometry: clinical revival of the pulse pressure waveform? Mayo Clin Proc. 2010;85:460-472.
54. Boutouyrie P, Achouba A, Trunet P; EXPLOR Trialist Group. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension. 2010;55:1314-1322.
55. Dart A, Cameron J, Gatzka C, et al. Similar effects of treatment on central and brachial blood pressures in older hypertensive subjects in the second Australian National Blood Pressure Trial. Hypertension. 2007;49:1242-1247.
56. Dhakam Z, McEniery C, Yasmin, Cockroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens. 2006;19:214-219.
57. Guido Grass G, Quarti-Trevano F, Mancia G. Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension. J Renin Angiotensin Aldosterone Syst. 2008;9:66-74.
58. Mahmud A, Feely J. Antihypertensive drugs and arterial stiffness. Expert Rev Cardiovasc Ther. 2003;1:65-78.
59. Manisty C, Zambanini A, Parker K, et al; Anglo-Scandinavian Cardiac Outcome Trial Investigators. Differences in the magnitude of wave reflection account for differential effects of amlodipine-versus atenolol-based regimens on central blood pressure an Anglo-Scandinavian Cardiac Outcome Trial substudy. Hypertension. 2009;54:724-730.
60. Matsui Y, Eguchi K, O'Rourke M, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension. 2009;54:716-723.
61. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004;17:118-123.
62. Munir S, Guilcher A, Kamalesh T, et al. Peripheral augmentation index defines the relationship between central and peripheral pulse pressure. Hypertension. 2008;51:112-118.
63. Protogerou A, Blacher J, Stergiou GS, Achimastos A, Safar ME. Blood pressure response under chronic antihypertensive drug therapy: the role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study. J Am Coll Cardiol. 2009;53:445-451.
64. Rehman A, Ismail SB, Naing L, Roshan TM, Rahman AR. Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among male hypertensive subjects with a known genetic profile. Am J Hypertens. 2007;20:184-189.
65. Uehara G, Takeda H. Relative effects of telmisartan, candesartan and losartan on alleviating arterial stiffness in patients with hypertension complicated by diabetes mellitus: an evaluation using the cardio-ankle vascular index (CAVI). J Int Med Res. 2008;36:1094-1102.
66. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor beyond blood pressure lowering: beyond blood pressure or beyond the brachial artery? J Hypertens. 2005;23:551-556.
67. Benetos A, Adamopoulos C, Bureau JM, et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation. 2002;105:1202-1207.
68. Kingwell BA, Waddell TK, Medley TL, Cameron JD, Dart AM. Large artery stiffness predicts ischemic threshold in patients with coronary artery disease. J Am Coll Cardiol. 2002;40:773-779.
69. Mackenzie I, Wilkinson I, Cockcroft J. Assessment of arterial stiffness in clinical practice. QJM. 2002;95:67-74.
70. McVeigh GE, Bratteli CW, Morgan DJ, et al. Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis: aging and arterial compliance. Hypertension. 1999;33:1392-1398.
71. Sutton-Tyrrell K, Mackey RH, Holubkov R, Vaitkevicius PV, Spurgeon HA, Lakatta EG. Measurement variation of aortic pulse wave velocity in the elderly. Am J Hypertens. 2001;14:463-468.
72. Vlachopoulos C, Alexopoulos N, Panagiotakos D, et al. Cigar smoking has an acute detrimental effect on arterial stiffness. Am J Hypertens. 2004;17:299-303.
73. Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension. 1999;33:1111-1117.
74. Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension. 1998;32: 570-574.
75. Davies J, Struthers A. Pulse wave analysis and pulse wave velocity: a critical review of their strenghs and weaknesses. J Hypertens. 2003;21: 463-472.
76. Safar M, Levy B, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular disease. Circulation. 2003;107:2864-2869.
77. Asmar R, Benetos A, Topouchian J, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement: validation and clinical application studies. Hypertension. 1995;26:485-490.
78. Vlachopoulos C, Alexopoulos N, Panagiotakos D, O'Rourke MF, Stefanadis C. Pressure altering agents affect central aortic pressure more than is apparent from upper limb measurements in hypertensive patients. The role of arterial wave reflections. Am J Hypertens. 2001;38:1456-1460.
79. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002;39:10-15.
80. Wilkinson I, Ian R, Hall I, et al. Pulse-wave analysis clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol. 2002;22:147-152.
81. Kakou A, Bezie Y, Mercier N, et al. Selective reduction of central pulse pressure under angio-tensin blockage in SHR: role of the fibronectin-α5β1 integrin complex. Am J Hypertens. 2009;22:711-717.
82. Agabiti-Rosei E, Heagerty AM, Rizzoni D. Effects of antihypertensive treatment on small artery remodeling. J Hypertens. 2009;27:1107-1114.
83. Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manage. 2009;5:353-360.
84. Safar M, Protogerou A, Blacher J. Central blood pressure under angiotensin and calcium channel blockade. Hypertension. 2009;54:704-706.
85. Williams B, Lacy P, Cruickshank J, et al; CAFE and ASCOT Investigators. Impact of statin therapy on central aortic pressures and hemodynamics principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) study. Circulation. 2009;119:53-61.